TScan Therapeutics Q3 EPS $(0.28) Beats $(0.30) Estimate, Sales $2.511M Beat $1.980M Estimate
Benzinga Newsdesk 11 months ago
EarningsEarnings BeatsNews
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 5.41 percent. This is a 12 percent decrease over losses of $(0.25) per share from
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 5.41 percent. This is a 12 percent decrease over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $2.511 million which beat the analyst consensus estimate of $1.980 million by 26.82 percent. This is a 139.37 percent increase over sales of $1.049 million the same period last year.